Invivyd (IVVD) to Release Earnings on Thursday

Invivyd (NASDAQ:IVVD) will be posting its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Invivyd to post earnings of ($0.50) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings results on Thursday, March 28th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.26). On average, analysts expect Invivyd to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Invivyd Stock Performance

IVVD opened at $2.51 on Wednesday. The firm has a market cap of $299.24 million, a P/E ratio of -1.39 and a beta of 0.89. The firm has a 50-day moving average of $3.24 and a 200 day moving average of $3.11. Invivyd has a fifty-two week low of $0.98 and a fifty-two week high of $5.20.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Guggenheim upgraded shares of Invivyd from a “neutral” rating to a “buy” rating and set a $9.00 price target for the company in a research report on Friday, April 5th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Invivyd in a report on Monday, March 25th. Finally, Morgan Stanley raised shares of Invivyd from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $4.00 to $10.00 in a report on Tuesday, March 26th.

About Invivyd

Invivyd, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2.